For the quarter ending 2026-03-31, ELTX has $22,689K in assets. $24,126K in debts. $14,948K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Restricted cash, current | - | 0 | 0 | 0 |
| Cash and cash equivalents | 14,948 | 18,563 | 20,611 | 22,088 |
| Prepaid expenses and other current assets | 1,252 | 748 | 854 | 510 |
| Total current assets | 16,200 | 19,311 | 21,465 | 22,598 |
| Property and equipment, net | 249 | 295 | 328 | 377 |
| Operating lease, right-of-use assets | 4,539 | 4,782 | 5,019 | 5,253 |
| Restricted cash, noncurrent | 706 | 704 | 702 | 700 |
| Other long-term prepaid assets | 995 | 770 | 770 | 600 |
| Total assets | 22,689 | 25,862 | 28,284 | 29,528 |
| Deferred research obligation | - | 0 | 0 | 0 |
| Accounts payable | 272 | 672 | 321 | 3,865 |
| Accrued expenses | 5,915 | 6,427 | 5,213 | 5,106 |
| Operating lease liability, current | 1,042 | 1,011 | 981 | 952 |
| Total current liabilities | 7,229 | 8,110 | 6,515 | 9,923 |
| Warrant liabilities | 3,599 | 2,615 | 3,877 | 3,821 |
| Operating lease liability, noncurrent | 3,823 | 4,094 | 4,356 | 4,613 |
| Long-term debt, net | 9,475 | 9,407 | 9,720 | 9,337 |
| Total liabilities | 24,126 | 24,226 | 24,468 | 27,694 |
| Common stock, 0.01 par value per share 300,000,000 shares authorized 18,654,350 shares and 17,814,762 shares issued at march31, 2026 and december31, 2025, respectively 18,639,895 and 17,800,307 outstanding as of march31, 2026 and december31, 2025, respectively | 186 | 178 | 173 | 163 |
| Treasury stock, at cost, 14,455 shares outstanding | 150 | 150 | 150 | 150 |
| Additional paid-in capital | 244,144 | 235,407 | 229,778 | 217,762 |
| Accumulated other comprehensive loss | -122 | -127 | -31 | -70 |
| Accumulated deficit | -245,495 | -233,672 | -225,954 | -215,871 |
| Total stockholders' (deficit) equity | -1,437 | 1,636 | 3,816 | 1,834 |
| Total liabilities and stockholders equity (deficit) | 22,689 | 25,862 | 28,284 | 29,528 |
Elicio Therapeutics, Inc. (ELTX)
Elicio Therapeutics, Inc. (ELTX)